Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

IDSA Disclaimer As of the time of this publication, updates have been made to IDSA's
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …

The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Importance SARS-CoV-2 infection has been associated with more severe disease and
death in patients with cancer. However, the implications of certain tumor types, treatments …

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus
disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression …

Background During the first wave of COVID-19, hydroxychloroquine (HCQ) was used off-
label despite the absence of evidence documenting its clinical benefits. Since then, a meta …

Introduction Passive antibody therapy has been used to immunize vulnerable people
against infectious agents. In this study, we aim to investigate the efficacy of convalescent …

Background A systematic review and meta-analysis was performed to estimate mortality in
adult patients with solid or hematological malignancies and SARS-CoV-2 infection. Methods …